[Venous insufficiency in the pregnant woman. Rheological correction by troxerutin].
We realized a double-blind randomized study in 26 pregnant with clinical symptoms of lower limbs venous insufficiency. Both groups were similar and received either (n = 12) troxerutine (4 g/day) or placebo (n = 14), during 30 days. Evaluation at J0 and J30 was both clinical and rheological by mean of Myrenne aggregometer. After blood shear rate of 600 s-1, two parameters were determined: M after roughly stopping shear rate, M1 after diminishing to shear rate of 3 s-1. Results exhibited steady values in patients receiving troxerutine while a significant increasing values in patients receiving placebo for the two parameters M and M1. That result in erythrocyte antiaggregating action of troxerutine, hence lowering viscosity action, in venous insufficiency during pregnancy.
Lefebvre
G
G
Service de Gynécologie-Obstétrique, Université Paris VI, CHU Pitié-Salpêtrière.
Lacombe
C
C
D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001809:Blood Viscosity / Q000187:drug effects; D004311:Double-Blind Method; D004903:Erythrocyte Aggregation / Q000187:drug effects; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006896:Hydroxyethylrutoside / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D007866:Leg / Q000098:blood supply*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D014652:Vascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology
D000925:Anticoagulants; D006896:Hydroxyethylrutoside; C005865:troxerutin
Insuffisance veineuse de la femme enceinte. Correction rhéologique par la troxérutine.